Pipeline
We are advancing a pipeline of innovative medicines in four therapeutic areas: Overdose caused by methamphetamine, fentanyl and their co-use; Accidental ADHD medication poisoning in children (Adderall and Ritalin); Reversal of neuromuscular blocking agents in anesthesia; Metabolic and neurodegenerative condition-induced CNS dysfunction. Our pioneering work has produced a first-in-class treatment, CS-1103, for methamphetamine
overdose, a critical public health crisis.
Candidate
In-vivo
POC
NDA
Phase
III
CS-1103
Reduce methamphetamine from the human body to reverse the effect of acute intoxication
Methamphetamine Overdose
cGMP
Manu.
Pre-Clinical
Dev.
IND
Phase
I
Phase
II
CS-1103
Reduce fentanyl from the human body to reverse the effect of acute intoxication
Fentanyl
Overdose
CS-1203
Reversal of overdose caused by co-use of fentanyl and methamphetamine
Overdose From Fentanyl & Methamphetamine Co-use
CS-110x
Reversal of accidental ADHD medication poisoning in children
ADHD Medication Overdose in Children
CS-110y
Reversal Agent for NMBA in Anesthesia
Reversal of the neuromuscular blocking agents in anesthesia
CS-110z
CNS dysfunction caused by metabolic disorders and neurodegenerative diseases
CNS Dysfunction Treatments
Undisclosed
Additional Indications
Additional programs utilizing our novel sequestration platform
Hover for more detail
Clear Scientific has received over $25 million in funding to pursue the development of our pipeline​
​